<DOC>
	<DOC>NCT00406497</DOC>
	<brief_summary>The purpose of this phase 2 study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of postoperative inflammation.</brief_summary>
	<brief_title>Study of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation</brief_title>
	<detailed_description>The objective is to assess efficacy endpoints in comparison with 0.1% BM ophthalmic solution, prior to investigation of the efficacy and safety of 0.05% DFBA ophthalmic emulsion in the treatment of postoperative intraocular inflammation.</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Difluprednate</mesh_term>
	<mesh_term>Fluprednisolone</mesh_term>
	<criteria>Patients undergoing intraocular surgery (cataract surgery, cataract surgery + implantation of intraocular lens, vitreous surgery, cataract surgery + implantation of intraocular lens + vitreous surgery) Patients with anterior chamber cell score ≥2 on the next day of surgery Male and female patients aged ≥20 years (on the day of obtaining informed consent) Patients giving written informed consent prior to initiation of the study Patients who did not meet all of the above inclusion criteria Patients receiving systemic administration of any corticosteroid or immunosuppressive drug, or topical application of corticosteroid ophthalmic ointment within 1 week before instillation of the investigational product Patients receiving topical injection of any corticosteroid in eyes before instillation of the investigational product (aqueous preparation: within 1 week before instillation of the investigational product, depot preparation: within 2 weeks before instillation of the investigational product) Patients receiving systemic administration of any nonsteroidal antiinflammatory drug or antiphlogistic enzyme Patients receiving instillation of any corticosteroid, nonsteroidal antiinflammatory ophthalmic solution or antiphologistic enzyme within 24 hours before ophthalmic examination prior to instillation of the investigational product (on the next day of surgery) (except instillation of nonsteroidal antiinflammatory ophthalmic solution at 3, 2, 1 and 0.5 hours before surgery) Patients with endogenous uveitis Patients planning to undergo surgery of the contralateral eye during the study period Patients with new intraocular bleeding after surgery Patients receiving gas or silicon oil in the vitreous body Patients with glaucoma or ocular hypertension (IOP on the next day of surgery ≥25 mmHg) Patients with superficial punctuate keratopathy or corneal ulcer Patients with any viral, bacterial or fungal keratoconjunctival disease Patients with allergy to any corticosteroid Patients requiring use of contact lens during the study period Women who were or might be pregnant, or lactating women Patients participating in another clinical study within 3 months before initiation of the present study Patients undergoing surgery under systemic anesthesia</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
</DOC>